Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · IEX Real-Time Price · USD
4.200
-0.445 (-9.58%)
Apr 25, 2024, 4:00 PM EDT - Market closed
Ocular Therapeutix Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Ocular Therapeutix stock have an average target of 16.5, with a low estimate of 11 and a high estimate of 24. The average target predicts an increase of 292.86% from the current stock price of 4.20.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for OCUL stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +280.95% | Apr 19, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $24 | Buy | Reiterates | $24 | +471.43% | Apr 16, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $24 | Buy | Reiterates | $24 | +471.43% | Mar 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $15 | Strong Buy | Maintains | $12 → $15 | +257.14% | Mar 13, 2024 |
| TD Cowen | TD Cowen | Hold Maintains $8 → $11 | Hold | Maintains | $8 → $11 | +161.90% | Mar 12, 2024 |
Financial Forecast
Revenue This Year
69.41M
from 58.44M
Increased by 18.76%
Revenue Next Year
86.70M
from 69.41M
Increased by 24.92%
EPS This Year
-0.85
from -1.02
EPS Next Year
-0.90
from -0.85
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 79.8M | 121.8M | 134.3M | 390.5M | 591.2M |
| Avg | 69.4M | 86.7M | 100.1M | 272.3M | 398.6M |
| Low | 61.6M | 69.0M | 76.0M | 188.0M | 249.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 36.5% | 75.5% | 54.9% | 290.2% | 117.1% |
| Avg | 18.8% | 24.9% | 15.4% | 172.1% | 46.4% |
| Low | 5.4% | -0.6% | -12.4% | 87.8% | -8.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.54 | -0.41 | -0.68 | 0.91 | 1.12 |
| Avg | -0.85 | -0.90 | -0.84 | 0.89 | 1.09 |
| Low | -1.89 | -1.68 | -1.12 | 0.85 | 1.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 26.6% |
| Avg | - | - | - | - | 23.0% |
| Low | - | - | - | - | 18.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.